United Kingdom

AIM ImmunoTech Expands Ampligen Patent Protection in Europe and U.K. Through 2041

OCALA, Fla., Sept. 2, 2026 AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharmaceutical company developing Ampligen® (rintatolimod), announced that...

By cGxPwire Editor
September 3, 2026

M&A

Codis Expands European CDMO with Catalent Acquisition

HAVERHILL, United Kingdom, July 6, 2026 Codis announced an agreement to acquire Catalent Pharma Solutions’ Nottingham, UK facility, a...

By cGxPwire Editor
July 8, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

United Kingdom

AIM ImmunoTech Expands Ampligen Patent Protection in Europe and U.K. Through 2041

Codis Expands European CDMO with Catalent Acquisition